

1 **Title Page**

2

3 ***Toxoplasma gondii* infection and testosterone congruently**
4 **increase tolerance of male rats for risk of reward forfeiture**

5

6 **Authors:** Donna Tan and Ajai Vyas

7

8 **Affiliations:**

9 School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore – 637551.

10

11 Running title: Risk tolerance in *Toxoplasma* infected rats

12

13 The number of words in the abstract: 149

14 The number of tables: 2

15 The number of figures: 4

16 The number of supplementary material: 0

17

18 Correspondence to:

19 Ajai Vyas,

20 School of Biological Sciences, Nanyang Technological University,

21 60 Nanyang Drive, Singapore – 637551.

22 Phone: +65 – 6513 7365. Fax: +65 6791 1604.

23 Email: avyas@ntu.edu.sg

24

25 Keywords: BART; Behavioral manipulation; Decision making; Impulsivity; Parasitism;
26 Steroids.

27 **Abstract**

28 Decision making under risk involves balancing the potential of gaining rewards with the
29 possibility of loss and/or punishment. Tolerance to risk varies between individuals.
30 Understanding the biological basis of risk tolerance is pertinent because excessive tolerance
31 contributes to adverse health and safety outcomes. Yet, not much is known about biological
32 factors mediating inter-individual variability in this regard. We investigate if latent
33 *Toxoplasma gondii* infection can cause risk tolerance. Using a rodent model of the balloon
34 analogous risk task, we show that latent *Toxoplasma gondii* infection leads to a greater
35 tolerance of reward forfeiture. Furthermore, effects of the infection on risk can be
36 recapitulated with testosterone supplementation alone, demonstrating that greater testosterone
37 synthesis by the host post-infection is sufficient to change risk tolerance. *Toxoplasma gondii*
38 is a frequent parasite of humans and animals. Thus, the infection status can potentially
39 explain some of the inter-individual variability in the risky decision making.

40 Introduction

41 Animals and humans typically make decisions in ambivalent situations and under risk of
42 forfeiture. Biological factors play an important role in such decision making. Two such
43 biological factors have attracted greater scientific interest: first, mesolimbic dopaminergic
44 system which pivots around nucleus accumbens; and second, steroid hormones secreted by
45 peripheral glands. Testosterone secreted by male gonads enhances risk-taking behavior in
46 human subjects (Coates and Herbert, 2008; Cooper et al., 2014; Peper et al., 2013; Stanton et
47 al., 2011). Extraneous testosterone can be used as a positive reinforcement in rodents (Wood,
48 2004; Wood et al., 2004), suggesting its ability to intersect with dopaminergic reward system
49 in the brain. Consistent with this, placement of testosterone or its metabolites in nucleus
50 accumbens facilitates conditioned place preference (Frye et al., 2002), again suggesting that
51 testosterone can activate mesolimbic dopaminergic pathways involved in decision making
52 under risk.

53 Interestingly a widely prevalent protozoan parasite (Jones et al., 2014), *Toxoplasma gondii*,
54 alters both testosterone synthesis and nucleus accumbal dopamine content in laboratory rats
55 (Lim et al., 2013; Tan et al., 2015). *Toxoplasma gondii* invades testes in this animal model
56 (Hari Dass et al., 2011; Vyas, 2013), resulting in a long-term increase of testosterone
57 synthesis (Lim et al., 2013). In addition, the infection results in greater synthesis of arginine
58 vasopressin in brain regions afferent to nucleus accumbens (Hari Dass and Vyas, 2014),
59 structural diminution of nucleus accumbens neurons and decrease in total dopamine
60 concentration (Tan et al., 2015). Retrospective studies suggest that chronic *Toxoplasma*
61 *gondii* infection enhances behaviors reminiscent of risk-taking in human subjects like being
62 involved in traffic accidents (Flegr et al., 2002; Flegr et al., 2009; Yereci et al., 2006).

63 These observations suggest that *Toxoplasma gondii* increases tolerance to reward forfeiture
64 through associated increase in testosterone availability. In this report, we experimentally test
65 this hypothesis.

66 **Materials and Methods**

67 **Animals**

68 Male Wistar rats were used. Rats were 8 weeks of age at the start of experiments, housed 2
69 per cage with 12 hours light-dark cycle (lights on at 7 AM). Rats were provided with *ad*
70 *libitum* access to food and water, except during operant experiments when rats were
71 maintained on a restricted diet to 85% of their free-feeding weight and allowance of 3 – 5 g
72 per week body weight gain. Animals were obtained from the vivarium of National University
73 of Singapore. All animal procedures were approved by Nanyang Technological University's
74 institutional animal care and use committee.

75 **Parasites**

76 *Toxoplasma gondii* tachyzoites of type 2 Prugniaud strain were maintained in human skin
77 fibroblast cultures. Infected fibroblasts were syringe-lysed to release tachyzoites. Animals
78 were either infected with tachyzoites (5×10^6 , intraperitoneal) or mock-infected with sterile
79 phosphate buffered saline. Eight weeks elapsed between infection and the start of behavioral
80 experiment; an incubation period consistent with the presence of chronic infection and
81 absence of acute parasitic proliferation (Vyas et al., 2007a).

82 **Castration and Testosterone treatment**

83 Surgery was performed using aseptic techniques under isoflurane anesthesia (2.5% gaseous
84 isoflurane with pure O₂). After placing animals in dorsal recumbency, testes were approached
85 through a mid-scrotal incision. Testes, vas deferens and testicular fat pad were bilaterally
86 removed followed by suturing of spermatic blood vessels. Scrotum was subsequently sutured.
87 One micro-infusion pump was placed subcutaneously supplying either vehicle (grape seed oil)
88 or testosterone cypionate. Microinfusion pumps (iPRECIO SMP-200; Durect) delivered their
89 cargo for several months requiring only monthly refills through the septum of the pumps

90 accessed through subcutaneous route. Pumps were programed to deliver 0.8 $\mu\text{l}/\text{day}$ of vehicle
91 or testosterone cypionate (200 mg/ml dissolved in grape seed oil; Pfizer) at a constant rate.
92 This dose of the testosterone is in slight excess to physiological norms of circulating
93 testosterone (Aubele et al., 2008).

94 Animals were given pre-operative prophylaxis antibiotic (Baytril 10mg/kg, sc; Bayer) and
95 pain relief (Carprofen 5 mg/kg, sc; Pfizer). After surgery, animals were housed singly for >3
96 days with supplemental pain relief daily (Carprofen 5 mg/kg, sc). Animals were re-housed
97 with prior cage-mates once wound healing was visually confirmed. At least one week elapsed
98 between surgery and start of food restriction for operant testing. Pumps were programed to
99 start infusion only after the recovery period.

100 **Quantification of serum Testosterone levels**

101 The method was modified from French (2013). 98 μL of serum and 2 μL of internal standard
102 (10 ng/mL Testosterone-2,3,4- $^{13}\text{C}_3$ in acetonitrile) were suspended in 1.1 mL of hexane:ethyl
103 acetate (90:10 v/v). The mixture was vortex-mixed and centrifuged at 3000 rpm for 10 min at
104 4°C. The aqueous layer was frozen on dry ice and the supernatant was pipetted into in a clean
105 tube. The solvent was then evaporated to dryness. Extracted testosterone was reconstituted in
106 100 μL of 20% acetonitrile. After reconstitution, the extracted sample was centrifuged at
107 13200 rpm for 10 min at 4°C and 85 μL of the supernatant was transferred to HPLC vials for
108 liquid chromatography electrospray tandem mass spectrometry (LCMS/MS) analysis for the
109 detection of testosterone. Detection of testosterone using LCMS/MS spectrometry is
110 described in Takyi-Williams et al. (2015). The quantitation limit of the method was 0.06
111 ng/mL and the method was linear within a range of 0.06 ng/mL to 1.95 ng/mL

112

113 Balloon analogous risk task

114 Operant performance under risk of reward forfeiture was measured using a balloon analogous
115 risk task, adapted from Jentsch et al. (2010) (Figure 1). Operant chambers used for training
116 and testing were provisioned with a house light and an internal stimulus lights (30x24x30 cm,
117 Med-Associates; programmed using K-Limbic, Conclusive Solution). Chambers were
118 enclosed in a sound-attenuating and ventilated outer cabinet. Ventilating exhaust fan mounted
119 on the outer cabinet provided a masking white noise (88 dB, linear scale). Operation of the
120 pellet dispenser delivered 45 mg food pellets (formula 5TUM; TestDiets) into the food
121 receptacle within the operant chamber. In addition, two retractable stainless steel response
122 levers were mounted on either side of the food delivery receptacle (8.5 cm above the floor, 7
123 cm lateral to the outer edge of food tray).

124 During initial training, rats were individually placed in the operant chambers and one of the
125 levers was extended for 30 minutes (phase 1). Each operant response of one lever press was
126 reinforced with the delivery of one food pellet. The process was repeated for the other lever
127 and animals were subsequently returned to their home cage. This phase of training was
128 repeated daily until all rats committed ≥ 60 responses for each lever during a 30-minute
129 session.

130 Subsequently, one of the levers was randomly designated as the 'add' lever (phase 2). The
131 left or right lever was designated as the 'add' lever in a counterbalanced manner across
132 animals; and kept consistent for each animal across training and testing. Rats were trained to
133 increase lever presses on the 'add' lever by successively increasing requisite responses from
134 1 to 3 and then 10 before delivery of one food pellet ensued (session duration = 20 minutes; 1
135 trial/day). This phase of the training continued till individual animals accumulated ≥ 30 lever
136 presses per session.

137 Next, subjects were trained in sessions comprising 54 trials (phase 3; 1 session/day). The ‘add’
138 lever was presented. Animals were required to accumulate a pre-determined number of lever
139 presses (varied randomly between 2 to 15) before the ‘add’ lever was retracted and an
140 alternative lever designated as the ‘cash-out’ was presented. Pressing the ‘cash-out’ lever
141 resulted in delivery of food pellets equal in number to presses of the ‘add’ lever required for
142 that trial.

143 After completion of training in the phase 3, rats began daily testing on the actual task (Figure
144 1; 54 trials/session, 1 session/day). Initially animals did not encounter any risk of reward
145 forfeiture (baseline). During each trial, ‘add’ and ‘cash-out’ levers were presented
146 simultaneously. Animals were required to execute >1 lever presses on the ‘add’ lever and
147 follow it up by pressing ‘cash-out’ lever. This resulted in delivery of delivery of food pellets
148 equal in number to the total number of ‘add’ lever presses. Pressing the ‘cash-out’ lever
149 before the ‘add’ lever resulted in an aborted trial without delivery of food. Failure to respond
150 within 3s resulted in a mistrial. Both mistrial and aborted trials resulted in zero yields. Only
151 gainful trials were included in the analysis. The process was repeated daily till they reached a
152 stable baseline ($p > 0.05$ for mean lever presses on ‘add’ lever when analyzed for three
153 consecutive days). Stable baseline was observed after 12-18 successive sessions had elapsed.

154 Once a stable baseline had been achieved, animals were tested under a risk of forfeiture. Each
155 successive press of the ‘add’ lever added one pellet to the accrued reward, but also linearly
156 increased the probability to total forfeiture. Three forfeiture probabilities were used (Δ
157 increase in forfeiture probability per ‘add’ press: 0, 0.111 and 0.167; assigned pseudo-
158 randomly and non-alternating; one session per day). For experiments involving castrated
159 animals with/without testosterone supplementation, only 0 and 0.167 risk schedule was used.
160 Trials comprising of zero risk of reward forfeiture were signaled by the illumination of a
161 house light during sessions. Response of animals in zero forfeiture trials before introduction

162 of risk (baseline) was compared with zero risk trials after introducing risk of forfeiture
163 (probe). Trials comprising of risk of reward forfeiture were signaled by the illumination of a
164 distinct stimulus light within the operant chamber. Mixed-risk sessions continued till stable
165 responding was achieved after 12 to 18 successive sessions. Probe trials with zero risk of
166 reward forfeiture were interspersed with forfeiture risk trials in a pseudorandom manner.
167 Mean lever presses during gainful trials was used as the endpoint during both baseline and
168 mixed-risk sessions.

169 Animals were assigned in the groups in a random manner. Training and subsequent testing
170 for control and infected animals was conducted >7 weeks post-infection. All animals in
171 control and infected groups were tested using continuous reinforcement schedule (FR1). For
172 experiment involving testosterone supplementation, gonad-intact animals were first trained to
173 a stable baseline before surgery. After at least one week of post-surgery recovery, animals
174 were again trained till stable baseline and then testing commenced. Castrated animals with or
175 without testosterone supplementation were tested at continuous reinforcement schedule (FR1),
176 although these animals had been initially trained on intermittent schedule (FR3) and then
177 shifted to FR1 till stable baseline had been achieved.

178 **Statistics**

179 Analysis of variance (ANOVA) was used to estimate the statistical significance of main
180 effects and/or interactions. Cumulative frequency distributions were fitted with Boltzmann
181 sigmoidal function. Paired t-test was used for orthogonal comparisons between baseline and
182 probe trials. Effect sizes (eta squared, η^2) for ANOVA were calculated as well as Cohen's d
183 for pairwise comparison (>0.8 interpreted as a large effect) (Cohen, 1977). Number of
184 animals is noted in figure legends.

185 Results

186 We quantified decision making under risk using a rodent version of the balloon analogous
187 risk task (BART, Figure 1) (Jentsch et al., 2010). Animals were first trained to press an “add-
188 lever” that increased the size of the upcoming reward (one food pellet per press) and a “cash-
189 out” lever that delivered the accrued reward.

190 Even in baseline conditions before introduction of risk, control animals executed relatively
191 few lever presses ($n = 14$ animals). For example, more than 50% of animals exhibited <3
192 lever presses per gainful trial in pre-risk episodes (Figure 2A, *black*; Table 1). We further
193 introduced risk whereby each press of the add-lever increased the probability of reward
194 forfeiture akin of a balloon being burst under increasing inflation. The probabilities of
195 balloon bursting were fixed at 0.111 or 0.167 per additional press during two separate
196 sessions (or an 11.1% and 16.7% incremental risk). Probe trials with zero risk of reward
197 forfeiture were interspersed with 11.1% and 16.7% forfeiture trials in a pseudorandom
198 manner. The mean numbers of add-lever presses, during baseline and in probe trials, were
199 quantified.

200 Performance of control and infected animals was compared at baseline and during post-risk
201 probe trials (repeated measure ANOVA: risk as within-subject and infection status as
202 between-subject source of variance). Analysis of variance showed significant main effects of
203 risk in interceding trials ($F_{1,24} = 57.05, p < 0.001, \eta^2 = 0.10$). Main effect of infection status
204 was not statistically significant ($F_{1,24} = 0.57, p = 0.457, \eta^2 = 0.02$). ANOVA revealed
205 significant interaction between risk and infection status ($F_{1,24} = 18.71, p < 0.001, \eta^2 = 0.03$).
206 Post-hoc comparisons demonstrated significant suppression of lever pressing by control
207 animals during probe trials, compared to baseline (Figure 2B, *left*; paired student t-test: $|t|_{13} =$
208 $5.15, p = 0.0002$; effect size: Cohen's $d = 1.11$). In contrast, lever pressing by the infected

209 animals during probe trials was comparable to paired baseline measurements (Figure 2B,
210 *right*; $|t|_{11} = 1.1$, $p = 0.295$; statistical power = 0.05). All animals gained comparable body
211 weight during the experimental period (independent sample t-test: $|t_8| = 0.203$; $p = 0.845$;
212 effect size: Cohen's $d = 0.13$).

213 In view of greater testosterone synthesis by *Toxoplasma gondii* infected animals (Lim et al.,
214 2013), we subsequently tested if testosterone was sufficient to increase tolerance to reward
215 forfeiture congruent to effects of the infection. Uninfected rats were castrated and implanted
216 with micro-infusion pump delivering either vehicle ($n = 7$ rats) or testosterone cypionate ($n =$
217 9 animals; dose = $160 \mu\text{g/day}$). We quantified amount of the testosterone circulating in blood
218 serum in vehicle- and testosterone-treated castrates. Castration reduced serum testosterone
219 levels in vehicle-treated rats to $0.137 \pm 0.0262 \text{ ng/mL}$ while supplementation restored serum
220 testosterone levels in testosterone-treated rats to $0.709 \pm 0.105 \text{ ng/mL}$. (independent sample t-
221 test: $|t|_{13} = 4.35$, $p = 0.0008$; effect size: Cohen's $d = 2.52$). Operant responses during baseline
222 were recorded (Figure 3A, Table 2), followed by trials with risk of reward forfeiture (16.7%)
223 and probe trials containing zero risk. Probe trials were interspersed with forfeiture trials in a
224 pseudorandom manner.

225 Performance of vehicle- and testosterone-treated animals was compared at baseline and
226 during post-risk probe trials (repeated measure ANOVA). Analysis of variance showed
227 significant main effects of risk in interceding trials ($F_{1,14} = 15.55$, $p = 0.001$, $\eta^2 = 0.15$).
228 Main effect of testosterone status was not statistically significant ($F_{1,14} = 0.21$, $p = 0.651$, η^2
229 $= 0.05$). ANOVA revealed significant interaction between risk and testosterone status ($F_{1,14} =$
230 5.19 , $p = 0.039$, $\eta^2 = 0.03$). Post-hoc comparisons demonstrated significant suppression of
231 lever pressing by vehicle-treated animals during probe trials, compared to baseline (Figure
232 3B, *left*; paired student t-test: $|t|_6 = 5.21$, $p = 0.002$; effect size: Cohen's $d = 1.57$). In contrast,
233 lever pressing by testosterone-treated animals during probe trials was not significantly

234 different compared to paired baseline measurements (Figure 3B, *right*; $|t|_8 = 1.3$, $p = 0.229$;
235 statistical power = 0.158). All animals gained comparable body weight during the
236 experimental period (independent sample t-test: $|t|_8 = 0.149$; $p = 0.885$; effect size: Cohen's d
237 = 0.14). Thus, testosterone treatment induced risk tolerance, similar to *Toxoplasma gondii*
238 infected animals.

239 Performance of control uninfected intact rats (Figure 2A, baseline and probe) was compared
240 with castrated animals receiving vehicle supplementation (Figure 3A, baseline and probe). A
241 two-way ANOVA revealed significant main effects of risk ($F_{1,38} = 13.96$, $p = 0.0006$, $\eta^2 =$
242 0.26). Main effect of experimental treatment was not statistically significant ($F_{1,38} = 0.32$, $p =$
243 0.575, $\eta^2 = 0.59$). Similarly no interaction between risk and experimental group was evident
244 ($F_{1,38} < 0.00$, $p = 0.995$, $\eta^2 < 0.01$).

245 We also compared operant responding of the treated and untreated animals during trials with
246 16.7% risk of reward forfeiture (frequency distribution depicted in Figure 2 and 3, blue).
247 Effect of *Toxoplasma gondii* infection on mean number of lever presses during 16.7% risk
248 trials did not reach statistical significance (% change relative to baseline trials pre-risk, mean
249 \pm SEM: -40.1 ± 4.8 % for control and -28.0 ± 5.1 % for infected; independent t-test: $|t|_{24} =$
250 1.73 $p = 0.096$). Similarly, effect of testosterone supplementation did not reach statistical
251 significance when compared to respective vehicle supplemented animals (mean \pm SEM: -39.7
252 ± 4.1 % for vehicle and -29.2 ± 4.8 % for testosterone; $|t|_{14} = 1.59$, $p = 0.135$). Baseline and
253 probe trials in this experimental design do not have determinate theoretical optima. In
254 contrast, trials with 16.7% risk of reward forfeiture represent theoretical optima of 3 to 4
255 lever presses per trial (Figure 4, left; gray line). For each individual animal, we calculated
256 ratio of trials with optimal operant responding (3 or 4 lever presses) relative to total number
257 of gainful trials. Trials with 1 or 7 lever presses were omitted from this calculation because
258 these trials are characterized by certain outcomes. *Toxoplasma gondii* infection increased

259 trials with economically optimal responses (Figure 4A, right; independent t-test: $|t|_{24} = 3.34$, p
260 = 0.0027; effect size: Cohen's $d = 1.32$). Similarly, testosterone supplementation in non-
261 infected animals resulted in increased frequency of optimal responding (Figure 4B, right; $|t|_{14}$
262 = 2.51, $p = 0.0243$; effect size: Cohen's $d = 1.23$).

263 Discussion

264 Several paradigms have been used to quantify decision making under risk in animals and
265 humans. As an endpoint, these tasks typically use suppression of operant responding due to a
266 decrease in probability of reward (Stopper and Floresco, 2011), an increase in probability of
267 aversive outcome (Simon et al., 2009) or an increase in risk of forfeiture (Jentsch et al., 2010;
268 Lejuez et al., 2002). Amongst these tests, BART exhibits good test-retest validity in both
269 human and rodent studies (Jentsch et al., 2010; White et al., 2008). Moreover, BART exhibits
270 considerable predictive validity in humans. For example, individual variation of riskiness in
271 BART can explain significant variation in self-reported risky behaviors including drug abuse,
272 gambling attitudes, driving sans seatbelts and sexual intercourse with multiple partners sans
273 protection (Hunt et al., 2005; Lejuez et al., 2003a; Lejuez et al., 2003b; Lejuez et al., 2002).
274 Similar predictive studies for risk-taking operant behavior have not yet been conducted;
275 barring a demonstration that pharmacological inactivation of orbitofrontal cortex reduces
276 risk-taking in this task (Jentsch et al., 2010). This is an important gap in the knowledge
277 because animal studies can provide a robust avenue to delineate biological mechanisms of
278 inter-individual variability in risk taking. In this backdrop, we describe that a frequent
279 parasitic infection of humans and animals (Jones et al., 2014; Webster, 1994) can decrease
280 risk aversion in a rodent model. Furthermore we show that sustained testosterone rise, akin to
281 that observed in the infected animals and humans (Flegr et al., 2008; Lim et al., 2013), is
282 sufficient to reduce risk aversion.

283 In this context some limitations of the current study are noteworthy. Our conclusions are
284 based on the observations that unlike corresponding controls *Toxoplasma gondii* infection or
285 testosterone treatment does not reduce operant responding in probe trials after intervening
286 exposure to the risk. Our observations do not provide unequivocal evidence of reduced
287 operant responding in the treatment groups during trials containing forfeiture risk. Moreover,

288 we did not measure testosterone levels in current cohort of infected animals and
289 corresponding controls. Our assumption of congruence between the infected animals and
290 testosterone supplemented animals is thus based on historical observations of greater
291 testosterone synthesis after the infection (Lim et al., 2013).

292 A significant number of human beings are infected with *Toxoplasma gondii* (Hill et al.,
293 2005). Traditionally, this infection has been thought of being asymptomatic and of little
294 clinical interest in immune-competent hosts. This traditional thought has been recently
295 challenged by observations that latent *Toxoplasma gondii* infection in healthy individuals
296 leads to personality changes and increased testosterone (Flegr, 2013; Flegr et al., 2011; Flegr
297 et al., 2008). Retrospective studies show that the infected individuals are more likely to be
298 involved in situations reminiscent of risk like traffic accidents (Flegr et al., 2002; Flegr et al.,
299 2009; Yerehi et al., 2006). These studies suggest that the infection is associated with risk
300 taking, but their experimental design does not confirm the directionality of cause-and-effect.
301 For example, it can be alternatively argued that individuals with greater risk taking propensity
302 engage in dietary practices that later increase their possibility to become infected. Using a
303 prospective design, the present study confirms that *Toxoplasma gondii* infection *causes* risky
304 behaviors, and that the increase can be recapitulated by rise in testosterone post-infection.
305 Given the high incidence of *Toxoplasma gondii* infection, this infection can possibly explain
306 part of the variance observed between individual for risky behaviors.

307 We note that the concept of risk has been used in economic and biological literature in two
308 divergent manners (Schonberg et al., 2011). The economic concept of risk centers on the
309 greater variability of outcomes around the same central tendency. In contrast, biologists have
310 often taken risk to reflect instrumental responses when reward must be balanced with
311 probability of aversive outcomes like punishment or loss. In this report, we use the later
312 articulation, showing greater tolerance of the infected or testosterone-treated male rats to risk

313 of reward forfeiture. Congruent to prior observations (Jentsch et al., 2010; Lejuez et al.,
314 2002), we also show that untreated animals are risk-averse and do not respond optimally as
315 an economically rational actor would in the face of the risk. Thus, effects described here
316 should be viewed as a reduction in risk aversion rather than an increase in risk seeking.

317 Several studies show that rats infected with *Toxoplasma gondii* lose their innate aversion to
318 cat odors (Berdoy et al., 2000); a phenotype that is believed to increase trophic transmission
319 of the parasite from rats to its definitive cat host (but also (Worth et al., 2013)). This
320 observation has often been presented as a specific and isolated behavioral change (Berdoy et
321 al., 1995a; Lamberton et al., 2008; Vyas et al., 2007a; Vyas et al., 2007b). Yet current
322 observations show that *Toxoplasma gondii* increases risk tolerance, in addition to increasing
323 approach to potentially risky cat odors. We posit that effects of infection represent a
324 behavioral syndrome represented by coordinated increase in risky behaviors rather than a
325 constrained reduction in kairomonal aversion only (Cézilly and Perrot- Minnot, 2010;
326 Thomas et al., 2010). Apropos, prior studies show that treatments that increase testosterone
327 also ‘embolden’ mice by increasing approach to predator odors (Kavaliers et al., 2001).
328 Moreover, effects of *Toxoplasma gondii* infection on aversion to cat odor can be rescued by
329 castration pre-infection (Lim et al., 2013), suggesting that effects of testosterone on risk
330 tolerance presented here are syndromically related to predator avoidance in this host-parasite
331 association. On the other hand, a more parsimonious account of observations reported here
332 will include the fact that we have used exogenous vehicle or testosterone supply in otherwise
333 castrated animals here. This binary comparison might not faithfully capture an incremental
334 change in testosterone concentration caused by *Toxoplasma gondii* infection.

335 Increased operant responding of the infected animals can be alternatively explained as
336 reflection of greater metabolic demands leading to greater motivation to seek food. Several
337 strands of evidence contradict this alternative. Control and *Toxoplasma gondii* infected

338 animals consume equal amount of food after twelve hours of food deprivation (Vyas et al.,
339 2007a). In addition the infection does not alter body weight gain (Thomas et al., 2010) and
340 urinary creatinine levels (Vasudevan et al., 2015), suggesting non-difference in anabolic and
341 catabolic processes. This is supported by continued investment of the infected rats in
342 energetically expensive behaviors like dominance and competition (Berdoy et al., 1995b).

343 Operant responding of untreated animals in this study remains below theoretical optima. This
344 suggests that effects of the infection or testosterone treatment reflect an increase in risk
345 tolerance; rather than instituting a risk preference over prior indifference. It should be noted
346 that BART uses operant responding as a proxy for decision making. The strength of this
347 proxy depends on construct validity of the BART, i.e. ability of operant responding in this
348 task to accurately reflect the construct of decision making under risk. This is supported by
349 positive association between BART responding and use of habit-forming substances,
350 gambling or unprotected sexual intercourse (Lejuez et al., 2002).

351 Testosterone is reported to have several cognitive effects. Subcutaneous supplementation of
352 testosterone in male rats result in reduced behavioral flexibility, manifested as a reduced
353 ability to shift from previously learned operant rules (Wallin and Wood, 2015). Similarly,
354 chronic testosterone increases instrumental responses in rats when greater rewards co-occur
355 with a greater risk of punishment (Cooper et al., 2014). These studies involve administration
356 of testosterone in gonad-intact male rats. Exogenous testosterone in these cases can result in
357 negative feedback on endogenous androgen production (Swerdlloff et al., 2002), thus
358 potentially complicating interpretations. Human subject with greater testosterone levels take
359 greater financial risk in the laboratory (Apicella et al., 2014) and accumulate greater financial
360 payoff during risky transactions on the real-world trading floor (Coates et al., 2009; Coates
361 and Herbert, 2008). Adult men with greater endogenous testosterone take greater risk in the
362 Iowa gambling task (Stanton et al., 2011) and adolescent boys with greater endogenous

363 testosterone exhibit a greater tolerance to risk-taking in BART (Peper et al., 2013). Cause and
364 effect relationships in these human studies remain understudied because of methodological
365 constraints. In this backdrop, we use castrated animals without endogenous source of
366 testosterone, thus circumventing the possibility of interaction between exogenously supplied
367 testosterone and testicular steroidogenesis. Thus, we show that the rise in testosterone is
368 *casually* linked to a greater risk tolerance. The effects of testosterone in this study could be
369 either due to its direct interaction with androgen receptor or its aromatization and subsequent
370 interaction of resulting estrogen with its receptors (Kavaliers et al., 2012; Kavaliers et al.,
371 2008). Testosterone is also known to be metabolized to 5 α -dihydrotestosterone, a potent
372 agonist of androgen receptors.

373 The data presented here suggest that *Toxoplasma gondii* infection results in a coordinated
374 increase in risk-taking behavior of the host. This provides us with a useful paradigm to better
375 understand biological changes mediating risky behaviors underpinning substance abuse,
376 pathological gambling, attention related disorders and high-risk behaviors (Winstanley,
377 2011).

378 **Data Accessibility**

379 All raw data will be made available in Dryad repository upon publication.

380 **Competing Interests**

381 We have no competing interests.

382 **Authors' Contributions**

383 DT designed and conceptualized experiments; conducted BART; conducted data collection
384 and statistical analysis. AV took part in conceptualization; conducted statistical analysis and
385 wrote the paper. All authors commented and gave final approval for publication.

386 **Acknowledgments**

387 This study was funded by Ministry of Education, Singapore. The authors would like to thank
388 John Takyi-Williams for his assistance in LCMS-MS work.

389 **Financial Disclosures**

390 All authors declare that they have no conflict of interest or financial disclosures.

391 **References**

- 392 Apicella, C.L., Dreber, A., Mollerstrom, J., 2014. Salivary testosterone change following
393 monetary wins and losses predicts future financial risk-taking. *Psychoneuroendocrinology* 39,
394 58-64.
- 395 Aubele, T., Kaufman, R., Montalmant, F., Kritzer, M., 2008. Effects of gonadectomy and
396 hormone replacement on a spontaneous novel object recognition task in adult male rats.
397 *Hormones and behavior* 54, 244-252.
- 398 Berdoy, M., Webster, J., Macdonald, D., 1995a. Parasite-altered behaviour: is the effect of
399 *Toxoplasma gondii* on *Rattus norvegicus* specific? *Parasitology* 111, 403-409.
- 400 Berdoy, M., Webster, J.P., Macdonald, D., 2000. Fatal attraction in rats infected with
401 *Toxoplasma gondii*. *Proceedings of the Royal Society of London. Series B: Biological*
402 *Sciences* 267, 1591-1594.
- 403 Berdoy, M., Webster, J.P., Macdonald, D.W., 1995b. Parasite-altered behaviour: is the effect
404 of *Toxoplasma gondii* on *Rattus norvegicus* specific? *Parasitology* 111 (Pt 4), 403-409.
- 405 Cézilly, F., Perrot- Minnot, M.J., 2010. Interpreting multidimensionality in parasite- induced
406 phenotypic alterations: panselectionism versus parsimony. *Oikos* 119, 1224-1229.
- 407 Coates, J.M., Gurnell, M., Rustichini, A., 2009. Second-to-fourth digit ratio predicts success
408 among high-frequency financial traders. *Proceedings of the National Academy of Sciences of*
409 *the United States of America* 106, 623-628.
- 410 Coates, J.M., Herbert, J., 2008. Endogenous steroids and financial risk taking on a London
411 trading floor. *Proceedings of the National Academy of Sciences of the United States of*
412 *America* 105, 6167-6172.
- 413 Cohen, J., 1977. *Statistical power analysis for the behavioral sciences* (rev. Lawrence
414 Erlbaum Associates, Inc.

- 415 Cooper, S.E., Goings, S.P., Kim, J.Y., Wood, R.I., 2014. Testosterone enhances risk
416 tolerance without altering motor impulsivity in male rats. *Psychoneuroendocrinology* 40,
417 201-212.
- 418 Flegr, J., 2013. Influence of latent *Toxoplasma* infection on human personality, physiology
419 and morphology: pros and cons of the *Toxoplasma*–human model in studying the
420 manipulation hypothesis. *The Journal of experimental biology* 216, 127-133.
- 421 Flegr, J., Havlíček, J., Kodym, P., Malý, M., Smahel, Z., 2002. Increased risk of traffic
422 accidents in subjects with latent toxoplasmosis: a retrospective case-control study. *BMC*
423 *Infect Dis* 2, 11.
- 424 Flegr, J., Klose, J., Novotná, M., Berenreitterová, M., Havlíček, J., 2009. Increased incidence
425 of traffic accidents in *Toxoplasma*-infected military drivers and protective effect RhD
426 molecule revealed by a large-scale prospective cohort study. *BMC Infect Dis* 9, 72.
- 427 Flegr, J., Lenochova, P., Hodny, Z., Vondrova, M., 2011. Fatal attraction phenomenon in
428 humans: cat odour attractiveness increased for *toxoplasma*-infected men while decreased for
429 infected women. *PLoS neglected tropical diseases* 5, e1389.
- 430 Flegr, J., Lindová, J., Kodym, P., 2008. Sex-dependent toxoplasmosis-associated differences
431 in testosterone concentration in humans. *Parasitology* 135, 427-431.
- 432 French, D., 2013. Development and validation of a serum total testosterone liquid
433 chromatography–tandem mass spectrometry (LC–MS/MS) assay calibrated to NIST SRM
434 971. *Clinica Chimica Acta* 415, 109-117.
- 435 Frye, C., Rhodes, M., Rosellini, R., Svare, B., 2002. The nucleus accumbens as a site of
436 action for rewarding properties of testosterone and its 5 α -reduced metabolites. *Pharmacology*
437 *Biochemistry and Behavior* 74, 119-127.

- 438 Hari Dass, S.A., Vasudevan, A., Dutta, D., Soh, L.J.T., Sapolsky, R.M., Vyas, A., 2011.
439 Protozoan parasite *Toxoplasma gondii* manipulates mate choice in rats by enhancing
440 attractiveness of males. *PLoS One* 6, e27229.
- 441 Hari Dass, S.A., Vyas, A., 2014. *Toxoplasma gondii* infection reduces predator aversion in
442 rats through epigenetic modulation in the host medial amygdala. *Mol Ecol* 23, 6114-6122.
- 443 Hill, D.E., Chirukandoth, S., Dubey, J., 2005. Biology and epidemiology of *Toxoplasma*
444 *gondii* in man and animals. *Animal Health Research Reviews* 6, 41-61.
- 445 Hunt, M.K., Hopko, D.R., Bare, R., Lejuez, C., Robinson, E., 2005. Construct Validity of the
446 Balloon Analog Risk Task (BART) Associations With Psychopathy and Impulsivity.
447 *Assessment* 12, 416-428.
- 448 Jentsch, J.D., Woods, J.A., Groman, S.M., Seu, E., 2010. Behavioral characteristics and
449 neural mechanisms mediating performance in a rodent version of the Balloon Analog Risk
450 Task. *Neuropsychopharmacology* 35, 1797-1806.
- 451 Jones, J.L., Parise, M.E., Fiore, A.E., 2014. Neglected parasitic infections in the United States:
452 toxoplasmosis. *The American journal of tropical medicine and hygiene* 90, 794-799.
- 453 Kavaliers, M., Choleris, E., Colwell, D.D., 2001. Brief exposure to female odors
454 "emboldens" male mice by reducing predator-induced behavioral and hormonal responses.
455 *Hormones and behavior* 40, 497-509.
- 456 Kavaliers, M., Clipperton-Allen, A., Cragg, C.L., Gustafsson, J.A., Korach, K.S., Muglia, L.,
457 Choleris, E., 2012. Male risk taking, female odors, and the role of estrogen receptors. *Physiol*
458 *Behav* 107, 751-761.
- 459 Kavaliers, M., Devidze, N., Choleris, E., Fudge, M., Gustafsson, J.A., Korach, K.S., Pfaff,
460 D.W., Ogawa, S., 2008. Estrogen receptors alpha and beta mediate different aspects of the
461 facilitatory effects of female cues on male risk taking. *Psychoneuroendocrinology* 33, 634-
462 642.

- 463 Lamberton, P., Donnelly, C., Webster, J., 2008. Specificity of the *Toxoplasma gondii*-altered
464 behaviour to definitive versus non-definitive host predation risk. *Parasitology* 135, 1143-1150.
- 465 Lejuez, C., Aklin, W.M., Jones, H.A., Richards, J.B., Strong, D.R., Kahler, C.W., Read, J.P.,
466 2003a. The balloon analogue risk task (BART) differentiates smokers and nonsmokers.
467 *Experimental and clinical psychopharmacology* 11, 26.
- 468 Lejuez, C., Aklin, W.M., Zvolensky, M.J., Pedulla, C.M., 2003b. Evaluation of the Balloon
469 Analogue Risk Task (BART) as a predictor of adolescent real-world risk-taking behaviours. *J*
470 *Adolesc* 26, 475-479.
- 471 Lejuez, C.W., Read, J.P., Kahler, C.W., Richards, J.B., Ramsey, S.E., Stuart, G.L., Strong,
472 D.R., Brown, R.A., 2002. Evaluation of a behavioral measure of risk taking: the Balloon
473 Analogue Risk Task (BART). *Journal of experimental psychology. Applied* 8, 75-84.
- 474 Lim, A., Kumar, V., Hari Dass, S.A., Vyas, A., 2013. *Toxoplasma gondii* infection enhances
475 testicular steroidogenesis in rats. *Molecular ecology* 22, 102-110.
- 476 Peper, J.S., Koolschijn, P.C., Crone, E.A., 2013. Development of risk taking: contributions
477 from adolescent testosterone and the orbito-frontal cortex. *Journal of cognitive neuroscience*
478 25, 2141-2150.
- 479 Schonberg, T., Fox, C.R., Poldrack, R.A., 2011. Mind the gap: bridging economic and
480 naturalistic risk-taking with cognitive neuroscience. *Trends in cognitive sciences* 15, 11-19.
- 481 Simon, N.W., Gilbert, R.J., Mayse, J.D., Bizon, J.L., Setlow, B., 2009. Balancing risk and
482 reward: a rat model of risky decision making. *Neuropsychopharmacology* 34, 2208-2217.
- 483 Stanton, S.J., Liening, S.H., Schultheiss, O.C., 2011. Testosterone is positively associated
484 with risk taking in the Iowa Gambling Task. *Hormones and behavior* 59, 252-256.
- 485 Stopper, C.M., Floresco, S.B., 2011. Contributions of the nucleus accumbens and its
486 subregions to different aspects of risk-based decision making. *Cognitive, Affective, &*
487 *Behavioral Neuroscience* 11, 97-112.

- 488 Swerdloff, R.S., Wang, C., Sinha Hikim, A.P., 2002. Hypothalamic-Pituitary-Gonadal axis in
489 men, in: Pfaff, D.W. (Ed.), Hormones, brain and behavior. Academic Press, pp. 1-36.
- 490 Takyi-Williams, J., Liu, C.-F., Tang, K., 2015. Ambient ionization MS for bioanalysis: recent
491 developments and challenges. *Bioanalysis* 7, 1901-1923.
- 492 Tan, D., Soh, L.J., Lim, L.W., Daniel, T.C., Zhang, X., Vyas, A., 2015. Infection of male rats
493 with *Toxoplasma gondii* results in enhanced delay aversion and neural changes in the nucleus
494 accumbens core. *Proceedings. Biological sciences / The Royal Society* 282, 20150042.
- 495 Thomas, F., Poulin, R., Brodeur, J., 2010. Host manipulation by parasites: a
496 multidimensional phenomenon. *Oikos* 119, 1217-1223.
- 497 Vasudevan, A., Kumar, V., Ning Chiang, Y., Yew, J.Y., Cheemadan, S., Vyas, A., 2015.
498 alpha2u-globulins mediate manipulation of host attractiveness in *Toxoplasma gondii*-*Rattus*
499 *norvegicus* association. *The ISME journal* 9, 2112-2115.
- 500 Vyas, A., 2013. Parasite-augmented mate choice and reduction in innate fear in rats infected
501 by *Toxoplasma gondii*. *The Journal of experimental biology* 216, 120-126.
- 502 Vyas, A., Kim, S.-K., Giacomini, N., Boothroyd, J.C., Sapolsky, R.M., 2007a. Behavioral
503 changes induced by *Toxoplasma* infection of rodents are highly specific to aversion of cat
504 odors. *Proceedings of the National Academy of Sciences* 104, 6442-6447.
- 505 Vyas, A., Kim, S.-K., Sapolsky, R.M., 2007b. The effects of *toxoplasma* infection on rodent
506 behavior are dependent on dose of the stimulus. *Neuroscience* 148, 342-348.
- 507 Wallin, K.G., Wood, R.I., 2015. Anabolic-androgenic steroids impair set-shifting and
508 reversal learning in male rats. *European neuropsychopharmacology : the journal of the*
509 *European College of Neuropsychopharmacology*.
- 510 Webster, J., 1994. Prevalence and transmission of *Toxoplasma gondii* in wild brown rats,
511 *Rattus norvegicus*. *Parasitology* 108, 407-411.

- 512 White, T.L., Lejuez, C.W., de Wit, H., 2008. Test-retest characteristics of the Balloon
513 Analogue Risk Task (BART). *Experimental and clinical psychopharmacology* 16, 565.
- 514 Winstanley, C.A., 2011. The utility of rat models of impulsivity in developing
515 pharmacotherapies for impulse control disorders. *British journal of pharmacology* 164, 1301-
516 1321.
- 517 Wood, R.I., 2004. Reinforcing aspects of androgens. *Physiol Behav* 83, 279-289.
- 518 Wood, R.I., Johnson, L.R., Chu, L., Schad, C., Self, D.W., 2004. Testosterone reinforcement:
519 intravenous and intracerebroventricular self-administration in male rats and hamsters.
520 *Psychopharmacology* 171, 298-305.
- 521 Worth, A.R., Lymbery, A.J., Thompson, R.A., 2013. Adaptive host manipulation by
522 *Toxoplasma gondii*: fact or fiction? *Trends in parasitology* 29, 150-155.
- 523 Yereli, K., Balcioğlu, I.C., Özbilgin, A., 2006. Is *Toxoplasma gondii* a potential risk for
524 traffic accidents in Turkey? *Forensic science international* 163, 34-37.
- 525

526 **Figure Legends**

527 **Figure 1.** Procedure employed for testing risk aversion using balloon analog risk task.
528 Adapted from Jentsch et al. (2010). Rats were trained on a stable baseline at 0% risk before
529 introduction of a mixed-risk schedule (probe trials interspersed with 11.1% and/or 16.7%
530 forfeiture probabilities) until stable performance.

531 **Figure 2.** Performance of control rats and *Toxoplasma gondii* infected rats in absence and
532 presence of risk of forfeiture (**A**). Only gainful trials are included, excluding mistrials and
533 trials that resulted in forfeiture. Both baseline (*black*) and probe trials (*red*) were identical,
534 except that probe trials were interspersed with trials containing risk of reward forfeiture
535 (*green* and *blue*) in a pseudorandom manner. The ordinate depicts the cumulative frequency
536 (%) for the mean number of lever presses during gainful trials. Solid lines represent a
537 Boltzmann sigmoidal fit of the data (minima and maxima constrained at 0% and 100%,
538 respectively; fit characteristics in Table 1). N = 14 for control and 12 for infected groups.
539 Presence of risk of reward forfeiture in interceding trials suppressed operant responding in
540 control, but not infected, animals (**B**). ***, $p < 0.001$, paired Student's t-test with Bonferroni
541 correction. **Inset:** Temporal sequence of the experiment.

542 **Figure 3.** Performance of castrated rats supplemented with vehicle or with testosterone, in
543 absence and presence of risk of reward forfeiture (**A**). Only gainful trials are included,
544 excluding mistrials and trials that resulted in forfeiture. The ordinate depicts the cumulative
545 frequency (%) for the mean number of lever presses. Solid lines represent a Boltzmann
546 sigmoidal fit of the data (minima and maxima constrained at 0% and 100%, respectively; fit
547 characteristics in Table 2). N = 7 for vehicle and 9 for testosterone supplemented animals.
548 Presence of risk of reward forfeiture in interceding trials suppressed operant responding in

549 vehicle-treated, but not testosterone-treated, animals (**B**). **, $p < 0.01$, paired Student's t-test
550 with Bonferroni correction. **Inset:** Temporal sequence of the experiment.

551 **Figure 4.** Performance during trials with 16.7% risk of forfeiture for control and *Toxoplasma*
552 *gondii* infected rats (**A**); and for castrates with vehicle or testosterone supplementation (**B**).
553 Only gainful trials are included, excluding mistrials and trials that resulted in forfeiture.
554 Panels in left depict mean actual yield of pellets experienced by individual subjects vis-à-vis
555 theoretical yield for 16.7% incremental risk as a function of lever presses. Ordinate in right
556 panels depict ratio of trials with optimal operant responding (3 or 4 lever presses) relative to
557 total number of gainful trials. Trials with 1 or 7 lever presses were omitted from this
558 calculation because these trials are characterized by certain outcomes. *, $p < 0.05$, **, $p <$
559 0.01, independent Student's t-test.

Table 1. Sigmoidal fit for cumulative frequencies of mean lever presses by control and infected animals.

	<i>Slope</i>	<i>V50</i>	<i>R</i> ²	<i>P (Kolmogorov-Smirnov test)</i>
<i>Baseline</i>				
Control	0.43	2.71	0.99	0.739
Infected	0.49	2.71	0.97	
<i>Probe</i>				
Control	0.32	1.94	0.99	<0.0001
Infected	0.51	2.33	0.99	
<i>Risk = 11.1%</i>				
Control	0.18	1.64	0.96	<0.0001
Infected	0.36	1.90	0.97	
<i>Risk = 16.7%</i>				
Control	0.18	1.55	0.98	0.979
Infected	0.19	1.80	0.98	

Boltzmann model; $Y = \text{Bottom} + ((\text{Top}-\text{Bottom})/(1 + \exp^{(V50-X/\text{Slope})}))$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 2. Sigmoidal fit for cumulative frequencies of mean lever presses by castrated and testosterone-supplemented animals.


	<i>Slope</i>	<i>V50</i>	<i>R</i> ²	<i>p</i> (<i>Kolmogorov-Smirnov test</i>)
<i>Baseline</i>				
Castrated	0.35	2.59	0.98	0.997
Supplemented	0.35	2.42	0.97	
<i>Probe</i>				
Castrated	0.23	1.96	0.91	<0.0001
Supplemented	0.45	2.19	0.98	
<i>Risk = 16.7%</i>				
Castrated	0.14	1.60	0.98	0.401
Supplemented	0.16	1.72	0.98	

Boltzmann model; $Y = \text{Bottom} + ((\text{Top}-\text{Bottom})/(1 + \exp^{(V50-X/\text{Slope})}))$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1
[Click here to download high resolution image](#)


Figure 1



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 2
[Click here to download high resolution image](#)


Figure 2



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 3
[Click here to download high resolution image](#)

Figure 3





1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 4

Figure 4
[Click here to download high resolution image](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

A



B

